Effect of Interferon Gamma as a Treatment for Post-aggressive Immunosuppression in Intensive Care Units, a Randomized Bayesian Double-blind Controlled Trial Versus Placebo
Abroad (travel likely)RecruitingPHASE2, PHASE3
Conditions
Post-aggressive Immunosuppression · Adult Patients Admitted to Intensive Care With Initial Severity (SOFA of the First 24 Hours Post-admission ≥ 6 · Adult Under Mechanical Ventilation, and Presenting an mHLA-DR Less Than 8,000AB/C
Simple summaryAI-assisted
This summary is produced by a language model and is experimental. It may be incomplete or inaccurate and is not a substitute for professional medical advice.
Locations
Dr de Roquetaillade, Paris, France
Contact: Study coordinator (Dr de Roquetaillade Charles, MD) · charles.de-roquetaillade@aphp.fr · 0149958442Pr Dépret, Paris, France
Contact: Study coordinator (Pr Dépret François, Professor) · francois.depret@aphp.fr · 01 42 49 95 70
Study leads
Charles De ROQUETAILLADE, MD
Study Chair
APHP(ASSISTANCE PUBLIQUE DES HOPITAUX DE PARIS